丙戊酸镁缓释片联合奥氮平治疗阿尔茨海默病患者的临床效果

林彩云 蔡齐健 卢仪

[摘要]目的 探讨丙戊酸镁缓释片联合奥氮平治疗阿尔茨海默病患者的临床效果。方法 选取我院2015年10月～2017年10月收治的80例阿尔茨海默病患者，分层抽样，分为治疗组和对照组，每组各40例。治疗组使用丙戊酸镁缓释片以及奥氮平联合治疗，对照组仅使用奥氮平治疗。治疗4周后，对其行为和意识进行躁狂量表（BRMS）评定，生命质量应用SF-36量表进行评定。分析两组BRMS评分和生命质量评分间的差异。结果 通过4周治疗，治疗组的BRMS评分明显低于对照组（P<0.05），治疗组的生命质量躯体功能评分、社会功能评分、活力评分、心理功能评分明显高于对照组，差异均有统计学意义（P<0.05）。结论 丙戊酸镁缓释片联合奥氮平治疗阿尔茨海默病患者具有积极作用，建议在临床工作中推广。

[关键词]丙戊酸镁缓释片；奥氮平；阿尔茨海默病

[中图分类号] R749.16 [文献标识码] A [文章编号] 1674-4721（2018）5（a）-0163-03

[Abstract]Objective To investigate the clinical effect of Magnesium Valproate Sustained Release Tablets combined with Olanzapine in the treatment of Alzheimer′s disease.Methods A total of 80 patients in our hospital from October 2015 to October 2017 were selected and divided into the treatment group and the control group by stratified sampling，40 cases in each group.The patients in the treatment group were treated with Magnesium Valproate Sustained Release Tablets and Olanzapine，while the control group was treated with Olanzapine only.After four weeks of treatment，the behavior and consciousness were evaluated by BRMS，and the SF-36 scale evaluated the quality of life.The difference between the manic state and the quality of life in the two groups was analyzed.Results After 4 weeks of treatment，the treatment group of patients with mania was significantly lower than that of the control group （P<0.05），quality of life include physical function in treatment group patients，social function，activity，psychological function was significantly higher than that in the control group，the differences were statistically significant（P<0.05）.Conclusion Magnesium Valproate Sustained Release Tablets combined with Olanzapine are able to control the behavioral and psychological symptoms of Alzheimer′s disease more quickly and effectively.It is suggested that to be promoted in clinical work.

[Key words]Magnesium Valproate Sustained Release Tablets；Olanzapine；Alzheimer ′s disease

阿爾茨海默病（Alzheimer ′s disease）是一种发病隐匿，进展性退行性神经系统疾病，临床上常见的表现为记忆缺失，语言功能丧失，认知功能丧失，执行力下降，甚至有些患者会出现神经障碍或者人格改变等心理疾病[1-3]。目前认为阿尔茨海默病的发病机制是人体蛋白质的凝固、聚合形成特征性的神经原纤维缠结和老年斑所致。在临床上，65岁以上的患者被称为老年性痴呆，65岁以下的患者称为早老年痴呆患者[4]。目前，对阿尔兹海默病的治疗主要是控制伴发的精神病理症状的对症治疗，药物主要分为精神症状药物和神经系统补益药品。目前应用的精神症状药物可分为抗焦虑药、抗抑郁药、抗精神症状药[5]。神经系统补益药主要分为作用于神经递质的药物和脑代谢复活药物[6]。近年来，临床上开始使用非典型抗精神病药，其良好的疗效及耐受性受到临床医师的广泛好评[7-8]。……